Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936221437> ?p ?o ?g. }
- W2936221437 endingPage "21" @default.
- W2936221437 startingPage "10" @default.
- W2936221437 abstract "Important advances in the understanding of the biology and mechanisms of tumor progression of urothelial carcinoma (UC) have been achieved over the past decade. The treatment landscape for advanced-stage, unresectable or metastatic UC has shifted dramatically over a short period of time, with 6 new therapeutic agents available for clinical use. The use of traditional chemotherapy and new immune checkpoints inhibitors (ICIs) directed at programmed cell-death protein 1 (PD-1) or its ligand has led to unprecedented survival benefits in selected patients with metastatic UC. Data show that anti-PD-1 ICIs are not only improving long-term clinical benefit, but also quality of life for patients in the second-line setting. In the front-line setting, regulatory agencies have restricted the indications of atezolizumab and pembrolizumab (both ICIs) to patients with PD-L1positivity with advanced UC and who are platinum-ineligible. Very recently, erdafitinib, a pan-FGFR inhibitor, has been granted accelerated approval by FDA for platinum-pretreated advanced metastatic UC with susceptible FGFR3 or FGFR2 genetic alterations. Enfortumab vedotin, an antibody-drug conjugate, have been granted breakthrough designation by the FDA for the treatment of metastatic UC. Here we review the clinical trial data that have established standard-of-care treatment for advanced-stage UC. In addition, mechanisms of resistance and biomarkers of response to platinum-based chemotherapies and immunotherapies are also discussed, along with the clinical benefits and limitations of these therapies." @default.
- W2936221437 created "2019-04-25" @default.
- W2936221437 creator A5009105768 @default.
- W2936221437 creator A5074756323 @default.
- W2936221437 date "2019-06-01" @default.
- W2936221437 modified "2023-10-11" @default.
- W2936221437 title "Management of metastatic bladder cancer" @default.
- W2936221437 cites W1525365346 @default.
- W2936221437 cites W1554602088 @default.
- W2936221437 cites W1586024750 @default.
- W2936221437 cites W1800122197 @default.
- W2936221437 cites W1820495241 @default.
- W2936221437 cites W1834390835 @default.
- W2936221437 cites W1855374361 @default.
- W2936221437 cites W1858135205 @default.
- W2936221437 cites W1867318780 @default.
- W2936221437 cites W1893740135 @default.
- W2936221437 cites W1941332786 @default.
- W2936221437 cites W1968487988 @default.
- W2936221437 cites W1976411264 @default.
- W2936221437 cites W1991064094 @default.
- W2936221437 cites W1994196015 @default.
- W2936221437 cites W1998757588 @default.
- W2936221437 cites W1999587370 @default.
- W2936221437 cites W2003665515 @default.
- W2936221437 cites W2013312714 @default.
- W2936221437 cites W2014960675 @default.
- W2936221437 cites W2017054455 @default.
- W2936221437 cites W2033775272 @default.
- W2936221437 cites W2041383926 @default.
- W2936221437 cites W2046702136 @default.
- W2936221437 cites W2047139557 @default.
- W2936221437 cites W2047320857 @default.
- W2936221437 cites W2047670537 @default.
- W2936221437 cites W2048519490 @default.
- W2936221437 cites W2052375870 @default.
- W2936221437 cites W2065855960 @default.
- W2936221437 cites W2068523052 @default.
- W2936221437 cites W2074546881 @default.
- W2936221437 cites W2090906593 @default.
- W2936221437 cites W2100039832 @default.
- W2936221437 cites W2101562875 @default.
- W2936221437 cites W2102116016 @default.
- W2936221437 cites W2103192876 @default.
- W2936221437 cites W2103257412 @default.
- W2936221437 cites W2104584442 @default.
- W2936221437 cites W2104845282 @default.
- W2936221437 cites W2114699723 @default.
- W2936221437 cites W2128288739 @default.
- W2936221437 cites W2136032744 @default.
- W2936221437 cites W2140858291 @default.
- W2936221437 cites W2145526926 @default.
- W2936221437 cites W2148562299 @default.
- W2936221437 cites W2151488185 @default.
- W2936221437 cites W2152194109 @default.
- W2936221437 cites W2152756917 @default.
- W2936221437 cites W2152762320 @default.
- W2936221437 cites W2156845957 @default.
- W2936221437 cites W2157244703 @default.
- W2936221437 cites W2162130153 @default.
- W2936221437 cites W2165427711 @default.
- W2936221437 cites W2259411705 @default.
- W2936221437 cites W2289712604 @default.
- W2936221437 cites W2291014203 @default.
- W2936221437 cites W2292562657 @default.
- W2936221437 cites W2294657755 @default.
- W2936221437 cites W2341548114 @default.
- W2936221437 cites W2343368549 @default.
- W2936221437 cites W2347141054 @default.
- W2936221437 cites W2414977199 @default.
- W2936221437 cites W2466711473 @default.
- W2936221437 cites W2473162054 @default.
- W2936221437 cites W2530516001 @default.
- W2936221437 cites W2537255595 @default.
- W2936221437 cites W2550856922 @default.
- W2936221437 cites W2559804019 @default.
- W2936221437 cites W2564433363 @default.
- W2936221437 cites W2581231749 @default.
- W2936221437 cites W2582671354 @default.
- W2936221437 cites W2588621824 @default.
- W2936221437 cites W2588916311 @default.
- W2936221437 cites W2604441970 @default.
- W2936221437 cites W2606515779 @default.
- W2936221437 cites W2671996661 @default.
- W2936221437 cites W2734446741 @default.
- W2936221437 cites W2745624257 @default.
- W2936221437 cites W2755607580 @default.
- W2936221437 cites W2760661635 @default.
- W2936221437 cites W2763048166 @default.
- W2936221437 cites W2763670669 @default.
- W2936221437 cites W2777192533 @default.
- W2936221437 cites W2790752991 @default.
- W2936221437 cites W2805915033 @default.
- W2936221437 cites W2883863660 @default.
- W2936221437 cites W2891866600 @default.
- W2936221437 cites W2922520449 @default.
- W2936221437 cites W4246715702 @default.
- W2936221437 doi "https://doi.org/10.1016/j.ctrv.2019.04.002" @default.